Table 1.
Patient characteristics
| NSCLC (N=129) | SCLC (N=26) | ||
|---|---|---|---|
| Sex | male | 75 (58.1%) | 11 (42.3%) |
| female | 54 (41.9%) | 15 (57.7%) | |
| Age (years) | mean (SD) | 64.7 (10.5) | 655 (8.8) |
| WHO-PS | 0 | 59 (46.8%) | 9 (34.6%) |
| 1 | 60 (47.6%) | 11 (42.3%) | |
| ≥2 | 7 (5.6%) | 6 (23.1%) | |
| FEV1 (%) | mean (SD) | 78 (22) | 71 (20) |
| Nicotine use | current smoker | 47 (38.8%) | 8 (33.3%) |
| no/ex smoker | 74 (61.2%) | 16 (66.7%) | |
| cTNM | I | 17 (13.4%) | - |
| II | 3 (2.4%) | 4 (15.4%) | |
| IIIA | 48 (37.8%) | 7 (26.9%) | |
| IIIB | 50 (39.4%) | 15 (57.7%) | |
| IV | 5 (4.0%) | - | |
| PLNS | 0 | 27 (22.9%) | NA |
| 1 | 19 (16.1%) | ||
| 2 | 31 (26.3%) | ||
| 3 | 14 (11.9%) | ||
| ≥4 | 27 (22.9%) | ||
| GTV (cc) | median (range) | 72 (0-763) | 62 (8-398) |
| Chemotherapy | no | 24 (18.6%) | 2 (7.7%) |
| sequential | 31 (24.1%) | 1 (3.8%) | |
| concomittant | 74 (57.4%) | 23 (88.5%) | |
| TTD (Gy) | mean (SD) | 61.6 (7.7) | 46.6* |
| OTT (days) | mean (SD) | 28 (7) | 22 (4) |
| MED (Gy) | mean (SD) | 24.4 (10.8) | 20.8 ( 9.3) |
| MAXED (Gy) | mean (SD) | 57.7 (14.1) | 44.3 (7.6) |
| MLD (Gy) | mean (SD) | 16.0 (3.4) | 14.1 (3.3) |
| Dead at 2 years | 64 (52.9%) | NA | |
| Dsyphagia ≥grade 3 | 14 (11.6%) | 3 (12.0%) | |
| Dyspnea ≥ grade 3 | 10 (8.8%) | 1 (4.8%) |
Abbreviations: SCLC = small cell lung cancer; NSCLC = non-small cell lung cancer; WHO-PS = World Health Organization performance status; FEV1 = forced expiratory volume (1 s)
PLNS = number of positive lymph node stations; GTV = gross tumor volume (primary + nodes)
TTD = total radiation dose; OTT = overall treatment time; MED = mean esophageal dose; MAXED = maximum esophageal dose; NA = not assessed
*
standard dose 45.0 Gy, two patients were not treated per protocol